P Giangrande
Overview
Explore the profile of P Giangrande including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neufeld E, Solimeno L, Quon D, Walsh C, Seremetis S, Cooper D, et al.
Haemophilia
. 2017 Jul;
23(6):821-831.
PMID: 28752639
Background: While there is substantial literature addressing the principles of general management of haemophilia, literature on perioperative management of haemostasis is scarce. Objective: The aim of this study was to...
2.
Hanley J, McKernan A, Creagh M, Classey S, McLaughlin P, Goddard N, et al.
Haemophilia
. 2017 Apr;
23(4):511-520.
PMID: 28370924
No abstract available.
3.
Drummond M, Houwing N, Slothuus U, Giangrande P
Haemophilia
. 2017 Jan;
23(2):e58-e66.
PMID: 28111847
Aim: Poorly conducted economic evaluations have the potential to mislead both clinicians, leading to inappropriate treatment choices, and payers who must decide on the reimbursement of treatment costs. This paper...
4.
Escobar M, Tehranchi R, Karim F, Caliskan U, Chowdary P, Colberg T, et al.
Haemophilia
. 2016 Aug;
23(1):67-76.
PMID: 27480487
Introduction: Surgery in patients with haemophilia B carries a high risk of excessive bleeding and requires adequate haemostatic control until wound healing. Nonacog beta pegol, a long-acting recombinant glycoPEGylated factor...
5.
Berger K, Schopohl D, Hilger A, Behr Gross M, Giangrande P, Peyvandi F, et al.
Haemophilia
. 2014 Dec;
21(1):4-20.
PMID: 25495927
Payers in European countries request studies with high levels of evidence for decision making also for rare diseases like haemophilia B (HB). The objective of the study was to determine...
6.
Giangrande P, Seitz R, Behr-Gross M, Berger K, Hilger A, Klein H, et al.
Haemophilia
. 2014 Apr;
20(3):322-5.
PMID: 24731129
This report summarizes recommendations relating to haemophilia therapy arising from discussions among experts from 36 European countries during the Kreuth III meeting in April 2013. To optimize the organization of...
7.
Ljung R, Karim F, Saxena K, Suzuki T, Arkhammar P, Rosholm A, et al.
J Thromb Haemost
. 2013 Apr;
11(7):1260-8.
PMID: 23578227
Background: A 40K glycoPEGylated, recombinant activated factor VII (rFVIIa) bypassing agent (N7-GP) with a prolonged half-life (15 h) compared with rFVIIa was developed as a potential candidate for bleed-preventive regimens...
8.
Caviglia H, Narayan P, Forsyth A, Giangrande P, Gilbert M, Goddard N, et al.
Haemophilia
. 2012 Jun;
18 Suppl 4:54-60.
PMID: 22726084
Inhibitors are a serious complication, considerably increasing the morbidity, mortality and cost of treatment in this patient group. The challenge of treating people with haemophilia (PWH) with inhibitors can be...
9.
Klukowska A, Laguna P, Waleszkiewicz-Majewska B, Peregud-Pogorzelski J, Kamienska E, Bignell P, et al.
Haemophilia
. 2012 Apr;
18(3):e67-9.
PMID: 22531023
No abstract available.
10.
Peyvandi F, Palla R, Menegatti M, Siboni S, Halimeh S, Faeser B, et al.
J Thromb Haemost
. 2012 Feb;
10(4):615-21.
PMID: 22321862
Background: The European Network of Rare Bleeding Disorders (EN-RBD) was established to bridge the gap between knowledge and practise in the care of patients with RBDs. Objectives: To explore the...